PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. 1980 January; 65(1): 109–120.
PMCID: PMC371345

Variant human phosphoribosylpyrophosphate synthetase altered in regulatory and catalytic functions.

Abstract

An inherited, structurally abnormal and superactive form of the enzyme 5-phosphoribosyl 1-pyrophosphate (PP-ribose-P) synthetase (EC 2.7.6.1) has been characterized in fibroblasts cultured from a 14-yr-old male (S.M.) with clinical manifestations of uric acid overproduction present since infancy. PP-ribose-P synthetase from the cells of this child showed four- to fivefold greater than normal resistance to purine nucleotide (ADP and GDP) feedback inhibition of enzyme activity and hyperbolic rather than sigmoidal inorganic phosphate (Pi) activation in incompletely dialyzed extracts. Excessive maximal velocity of the enzyme reaction catalyzed by the mutant enzyme was indicated by: enzyme activities twice those of normal at all concentrations of Pi in chromatographed fibroblast extracts; normal affinity constants for substrates and for the activator, Mg2+; and twofold greater than normal activity per immunoreactive enzyme molecule. The mutant enzyme thus possessed deficient regulatory and superactive catalytic properties, two mechanisms previously demonstrated individually to underlie the excessive PPRribose-P and uric acid synthesis of affected members of families with superactive PP-ribose-P synthetases. Increased PP-ribose-P concentration (4-fold) and generation (2.7-fold) and enhanced rates of PP-ribose-P dependent purine synthetic reactions, including purine synthesis de novo, in S.M. fibroblasts confirmed the functional significance of this patient's mutant enzyme. Diminished stability of the variant PP-ribose-P synthetase was manifested in vitro by increased thermal lability and in vivo by deficiency of enzyme activity at Pi concentrations greater than 0.3 mM in hemolysates and by an accelerated, age-related decrement in enzyme activity in lysates of erythrocytes separated by specific density. Despite the diminished amount of PP-ribose-P synthetase in the S.M. erythrocyte population, S.M. erythrocytes had increased PP-ribose-P concentration and increased rates of incorporation of [14C]adenine and hypoxanthine into acid-soluble nucleotides during incubation at 1 mM Pi. These findings provided further confirmation of the extent to which PP-ribose-P synthesis is modulated in the normal cell at physiological Pi concentration by purine nucleotide inhibition of PP-ribose-P synthetase. The activity and kinetic characteristics of PP-ribose-P synthetase from fibroblasts of the mother of patient S.M. indicated that this woman was a heterozygous carrier of the enzyme defect expressed in hemizygous manner by her son.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hershko A, Razin A, Mager J. Regulation of the synthesis of 5-phosphoribosyl-I-pyrophosphate in intact red blood cells and in cell-free preparations. Biochim Biophys Acta. 1969 Jun 17;184(1):64–76. [PubMed]
  • Bagnara AS, Letter AA, Henderson JF. Multiple mechanisms of regulation of purine biosynthesis de novo in intact tumor cells. Biochim Biophys Acta. 1974 Dec 20;374(3):259–270. [PubMed]
  • Switzer RL. Regulation and mechanism of phosphoribosylpyrophosphate synthetase. I. Purification and properties of the enzyme from Salmonella typhimurium. J Biol Chem. 1969 Jun 10;244(11):2854–2863. [PubMed]
  • Switzer RL. Regulation and mechanism of phosphoribosylpyrophosphate synthetase. 3. Kinetic studies of the reaction mechanism. J Biol Chem. 1971 Apr 25;246(8):2447–2458. [PubMed]
  • Switzer RL, Sogin DC. Regulation and mechanism of phosphoribosylpyrophosphate synthetase. V. Inhibition by end products and regulation by adenosine diphosphate. J Biol Chem. 1973 Feb 10;248(3):1063–1073. [PubMed]
  • Wong PC, Murray AW. 5-Phosphoribosyl pyrophosphate synthetase from Ehrlich ascites tumor cells. Biochemistry. 1969 Apr;8(4):1608–1614. [PubMed]
  • Fox IH, Kelley WN. Human phosphoribosylpyrophosphate synthetase. Kinetic mechanism and end product inhibition. J Biol Chem. 1972 Apr 10;247(7):2126–2131. [PubMed]
  • Roth DG, Shelton E, Deuel TF. Purification and properties of phosphoribosyl pyrophosphate synthetase from rat liver. J Biol Chem. 1974 Jan 10;249(1):291–296. [PubMed]
  • Roth DG, Deuel TF. Stability and regulation of phosphoribosyl pyrophosphate synthetase from rat liver. J Biol Chem. 1974 Jan 10;249(1):297–301. [PubMed]
  • Becker MA, Kostel PJ, Meyer LJ. Human phosphoribosylpyrophosphate synthetase. Comparison of purified normal and mutant enzymes. J Biol Chem. 1975 Sep 10;250(17):6822–6830. [PubMed]
  • Fox IH, Kelley WN. Human phosphoribosylpyrophosphate synthetase. Distribution, purification, and properties. J Biol Chem. 1971 Sep 25;246(18):5739–5748. [PubMed]
  • Becker MA, Meyer LJ, Huisman WH, Lazar C, Adams WB. Human erythrocyte phosphoribosylpyrophosphate synthetase. Subunit analysis and states of subunit association. J Biol Chem. 1977 Jun 10;252(11):3911–3918. [PubMed]
  • Meyer LJ, Becker MA. Human erythrocyte phosphoribosylpyrophosphate synthetase. Dependence of activity on state of subunit association. J Biol Chem. 1977 Jun 10;252(11):3919–3925. [PubMed]
  • Sperling O, Boer P, Persky-Brosh S, Kanarek E, De Vries A. Altered kinetic property of erythrocyte phosphoribosylpsyrophosphate synthetase in excessive purine production. Rev Eur Etud Clin Biol. 1972 Aug-Sep;17(7):703–706. [PubMed]
  • Sperling O, Eilam G, Sara-Persky-Brosh, De Vries A. Accelerated erythrocyte 5-phosphoribosyl-1-pyrophosphate synthesis. A familial abnormality associated with excessive uric acid production and gout. Biochem Med. 1972 Aug;6(4):310–316. [PubMed]
  • Sperling O, Persky-Brosh S, Boer P, De Vries A. Human erythrocyte phosphoribosylpyrophosphate synthetase mutationally altered in regulatory properties. Biochem Med. 1973 Jun;7(3):389–395. [PubMed]
  • Zoref E, De Vries A, Sperling O. Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts. J Clin Invest. 1975 Nov;56(5):1093–1099. [PMC free article] [PubMed]
  • Becker MA, Meyer LJ, Seegmiller JE. Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity. Am J Med. 1973 Aug;55(2):232–242. [PubMed]
  • Becker MA, Kostel PJ, Meyer LJ, Seegmiller JE. Human phosphoribosylpyrophosphate synthetase: increased enzyme specific activity in a family with gout and excessive purine synthesis. Proc Natl Acad Sci U S A. 1973 Oct;70(10):2749–2752. [PubMed]
  • Becker MA. Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction. J Clin Invest. 1976 Feb;57(2):308–318. [PMC free article] [PubMed]
  • Fox IH, Kelley WN. Phosphoribosylpyrophosphate in man: biochemical and clinical significance. Ann Intern Med. 1971 Mar;74(3):424–433. [PubMed]
  • Zoref E, de Vries A, Sperling O. X-linked pattern of inheritance of gout due to mutant feedback-resistant phosphoribosylpyrophosphate synthetase. Adv Exp Med Biol. 1977;76A:287–292. [PubMed]
  • Yen RC, Adams WB, Lazar C, Becker MA. Evidence for X-linkage of human phosphoribosylpyrophosphate synthetase. Proc Natl Acad Sci U S A. 1978 Jan;75(1):482–485. [PubMed]
  • Nyhan WL, James JA, Teberg AJ, Sweetman L, Nelson LG. A new disorder of purine metabolism with behavioral manifestations. J Pediatr. 1969 Jan;74(1):20–27. [PubMed]
  • Rosenbloom FM, Henderson JF, Caldwell IC, Kelley WN, Seegmiller JE. Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem. 1968 Mar 25;243(6):1166–1173. [PubMed]
  • LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed]
  • HENDERSON JF. Feedback inhibition of purine biosynthesis in ascites tumor cells. J Biol Chem. 1962 Aug;237:2631–2635. [PubMed]
  • Kelley WN, Greene ML, Rosenbloom FM, Henderson JF, Seegmiller JE. Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout. Ann Intern Med. 1969 Jan;70(1):155–206. [PubMed]
  • Boyle JA, Raivio KO, Becker MA, Seegmiller JE. Effects of nicotinic acid on human fibroblast purine biosynthesis. Biochim Biophys Acta. 1972 May 10;269(2):179–183. [PubMed]
  • Kelley WN, Meade JC. Studies on hypoxanthine-guanine phosphoribosyltransferase in fibroblasts from patients with the Lesch-Nyhan syndrome. Evidence for genetic heterogeneity. J Biol Chem. 1971 May 10;246(9):2953–2958. [PubMed]
  • Kelley WN. Studies on the adenine phosphoribosyltransferase enzyme in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase. J Lab Clin Med. 1971 Jan;77(1):33–38. [PubMed]
  • Raivio KO, Seegmiller E. Adenine, hypoxanthine and guanine metabolism in fibroblasts from normal individuals and from patients with hypoxanthine phosphoribosyltransferase deficiency. Biochim Biophys Acta. 1973 Mar 19;299(2):273–282. [PubMed]
  • HENDERSON JF, KHOO MK. AVAILABILITY OF 5-PHOSPHORIBOSYL 1-PYROPHOSPHATE FOR RIBONUCLEOTIDE SYNTHESIS IN EHRLICH ASCITES TUMOR CELLS IN VITRO. J Biol Chem. 1965 Jun;240:2358–2362. [PubMed]
  • Henderson JF, Rosenbloom FM, Kelley WN, Seegmiller JE. Variations in purine metabolism of cultured skin fibroblasts from patients with gout. J Clin Invest. 1968 Jul;47(7):1511–1516. [PMC free article] [PubMed]
  • Johnson MG, Rosenweig S, Switzer RL, Becker MA, Seegmiller JE. Evaluation of the role of 5-phosphoribosyl-alpha-1-pyrophosphate synthetase in congenital hyperuricemia and gout: a simple isotopic assay and an activity stain for the enzyme. Biochem Med. 1974 Jul;10(3):266–275. [PubMed]
  • Kelley WN, Rosenbloom FM, Henderson JF, Seegmiller JE. A specific enzyme defect in gout associated with overproduction of uric acid. Proc Natl Acad Sci U S A. 1967 Jun;57(6):1735–1739. [PubMed]
  • Beardmore TD, Cashman JS, Kelley WN. Mechanism of allopurinol-mediated increase in enzyme activity in man. J Clin Invest. 1972 Jul;51(7):1823–1832. [PMC free article] [PubMed]
  • DANON D, MARIKOVSKY V. DETERMINATION OF DENSITY DISTRIBUTION OF RED CELL POPULATION. J Lab Clin Med. 1964 Oct;64:668–674. [PubMed]
  • Martin DW, Jr, Maler BA. Phosphoribosylpyrophosphate synthetase is elevated in fibroblasts from patients with the Lesch-Nyhan syndrome. Science. 1976 Jul 30;193(4251):408–411. [PubMed]
  • Rubin CS, Balis ME, Piomelli S, Berman PH, Dancis J. Elevated AMP pyrophosphorylase activity in congenital IMP pyrophosphorylase deficiencey (Lesch-Nyhan disease). J Lab Clin Med. 1969 Nov;74(5):732–741. [PubMed]
  • Sorel RH, Roseboom H. High-performance liquid chromatographic analysis of nalidixic acid in plasma after alkylation with methyl iodide. J Chromatogr. 1979 Mar 1;162(3):461–465. [PubMed]
  • LYON MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature. 1961 Apr 22;190:372–373. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation